Drug Name: | Nefazodone (83366-66-9) |
---|---|
PubChem ID: | 4449 |
SMILES: | CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl |
InchiKey: | VRBKIVRKKCLPHA-UHFFFAOYSA-N |
Therapeutic Category: | Antidepressive Agents, Central Nervous System Agents, Psychotropic Drugs |
Molecular Weight (dalton) | : | 470.017 |
LogP | : | 3.5519 |
Ring Count | : | 3 |
Hydrogen Bond Acceptor Count | : | 7 |
Hydrogen Bond Donor Count | : | 0 |
Total Polar Surface Area | : | 55.53 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|---|---|---|---|
Carbamazepine (298-46-4) | Raise Serum Carbamazepine Levels | Synergistic | Both drugs are metabolised by the cytochrome P450 isoenzyme CYP3A4. Nefazodone is known to inhibit CYP3A4, whereas carbamazepine is a potent inducer of CYP3A4. Hence concurrent use reduces carbamazepine metabolism | Nefazodone-induced carbamazepine toxicity |
Terfenadine (50679-08-8) | Prolongs The Qt Interval | Synergistic | Nefazodone inhibits the metabolism of terfenadine | Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation |
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Hepatotoxicity | Cytochrome P450 3A4 (P08684) | The metabolism of NEF and OH-NEF to each of their active metabolites is catalysed mainly by CYP3A4@ which is in agreement with clinical reports of drug--drug interactions of nefazodone with substrates and inhibitors of CYP3A4 [ ADR Type 2 ] | Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category